Sequential administration of interferon-γ, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma:: Results of a phase II trial

Various cytokine combinations have been tested for efficacy in the treatment of metastatic renal cell carcinoma (MRCC). Because several immunologic synergisms between granulocyte-macrophage colony-stimulating-factor (GM-CSF) and interleukin-2 (IL-2) have been demonstrated, this phase II trial was conducted on the efficacy and toxicity of subcutaneous, sequentially administered, interferon-gamma (IFN gamma), GM-CSF, and IL-2. Fifty-five consecutive patients with MRCC were treated with 100 mug recombinant IFN gamma 1b administered thrice weekly during weeks 1 and 4, followed by 400 mug GM-CSF on 5 consecutive days during weeks 2 and 5. In weeks 3 and 6, patients received 4.5 MU recombinant IL-2 from days 1 to 4. The treatment was repeated every 8 weeks. Five (10%) of patients experienced an objective response (complete response [CR]: 2%, partial response [PR]: 8%). Fourteen (26%) patients had stable disease with a median duration of 19 months (6-47+). The median overall survival was 12 months (range: 0.3-44 months), No toxicity greater than World Health Organization grade II was observed, with fever (43%) and erythema (43%) being the most frequent side effects. Compared with other phase II trials with IFN gamma and IL-2 alone, the addition of GM-CSF failed to improve response or survival in patients with MRCC.